CNGA3 and choroideremia: This modality of treatment has shown efficacy in clinical trials treating RPE65-associated Leber congenital amaurosis (LCA) [8], CHM-associated choroideremia [9,10], CNGA3-related achromatopsia [11], and MERTK-associated retinitis pigmentosa [12].